# Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

> **NCT05070403** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 25 (estimated)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Afatinib 40 MG

## Key facts

- **NCT ID:** NCT05070403
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-01
- **Primary completion:** 2027-02
- **Final completion:** 2028-03
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05070403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05070403, "Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05070403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*